How is anabolic steroid use different from testosterone replacement therapy?
What are anabolic steroids?
Are they any medical indications for use of anabolic steroids?
New FDA warning on abuse and dependence of testosterone
Salient differences between anabolic steroid abuse and testosterone therapy
Bottom Line
References:
1. Basaria, S., Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab, 2010. 95(4): p. 1533-43.
2. West, D.W. and S.M. Phillips, Anabolic processes in human skeletal muscle: restoring the identities of growth hormone and testosterone. Phys Sportsmed, 2010. 38(3): p. 97-104.
3. Fitch, K.D., Androgenic-anabolic steroids and the Olympic Games. Asian J Androl, 2008. 10(3): p. 384-90.
4. Angell, P., et al., Anabolic steroids and cardiovascular risk. Sports Med, 2012. 42(2): p. 119-34.
5. Angell, P.J., et al., Anabolic steroid use and longitudinal, radial, and circumferential cardiac motion. Med Sci Sports Exerc, 2012. 44(4): p. 583-90.
6. Angell, P.J., et al., Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician. Br J Sports Med, 2012. 46 Suppl 1: p. i78-84.
7. Angell, P.J., et al., Ventricular structure, function, and focal fibrosis in anabolic steroid users: a CMR study. Eur J Appl Physiol, 2014. 114(5): p. 921-8.
8. Baggish, A.L., et al., Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail, 2010. 3(4): p. 472-6.
9. Deligiannis, A.P. and E.I. Kouidi, Cardiovascular adverse effects of doping in sports. Hellenic J Cardiol, 2012. 53(6): p. 447-57.
10. Garevik, N., et al., Long term perturbation of endocrine parameters and cholesterol metabolism after discontinued abuse of anabolic androgenic steroids. J Steroid Biochem Mol Biol, 2011. 127(3-5): p. 295-300.
11. Pope, H.G., Jr., et al., Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev, 2014. 35(3): p. 341-75.
12. Kersey, R.D., et al., National Athletic Trainers' Association position statement: anabolic-androgenic steroids. J Athl Train, 2012. 47(5): p. 567-88.
13. Hoffman, J.R., et al., Position stand on androgen and human growth hormone use. J Strength Cond Res, 2009. 23(5 Suppl): p. S1-S59.
14. Achar, S., A. Rostamian, and S.M. Narayan, Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol, 2010. 106(6): p. 893-901.
15. Morales, A., The long and tortuous history of the discovery of testosterone and its clinical application. J Sex Med, 2013. 10(4): p. 1178-83.
16. Hoberman, J.M. and C.E. Yesalis, The history of synthetic testosterone. Sci Am, 1995. 272(2): p. 76-81.
17. Dotson, J.L. and R.T. Brown, The history of the development of anabolic-androgenic steroids. Pediatr Clin North Am, 2007. 54(4): p. 761-9, xi.
18. Kochakian, C.D., The evolution from "the male hormone" to anabolic- androgenic steroids. Ala J Med Sci, 1988. 25(1): p. 96-102.
19. Joseph, J.F. and M.K. Parr, Synthetic androgens as designer supplements. Curr Neuropharmacol, 2015. 13(1): p. 89-100.
20. Wu, C. and J.R. Kovac, Novel Uses for the Anabolic Androgenic Steroids Nandrolone and Oxandrolone in the Management of Male Health. Curr Urol Rep, 2016. 17(10): p. 72.
21. Pan, M.M. and J.R. Kovac, Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness. Transl Androl Urol, 2016. 5(2): p. 213-9.
22. WADA., The World Anti-Doping Code, in The 2015 Prohibited List - International Standard. 2015. p. http://www.usada.org/wp-content/uploads/wada-2015-prohibited-list-en.pdf.
23. Basaria, S., J.T. Wahlstrom, and A.S. Dobs, Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab, 2001. 86(11): p. 5108-17.
24. Taylor, W.N., Anabolic Therapy in Modern Medicine 2002: McFarland.
25. Morley, J.E., Anabolic steroids and frailty. J Am Med Dir Assoc, 2010. 11(8): p. 533-6.
26. Bhasin, S., The brave new world of function-promoting anabolic therapies: testosterone and frailty. J Clin Endocrinol Metab, 2010. 95(2): p. 509-11.
27. Bross, R., M. Javanbakht, and S. Bhasin, Anabolic interventions for aging-associated sarcopenia. J Clin Endocrinol Metab, 1999. 84(10): p. 3420-30.
28. Farooqi, V., et al., Anabolic steroids for rehabilitation after hip fracture in older people. Cochrane Database Syst Rev, 2014. 10: p. CD008887.
29. Hedstrom, M., et al., Positive effects of anabolic steroids, vitamin D and calcium on muscle mass, bone mineral density and clinical function after a hip fracture. A randomised study of 63 women. J Bone Joint Surg Br, 2002. 84(4): p. 497-503.
30. Hohmann, E., et al., Anabolic steroids after total knee arthroplasty. A double blinded prospective pilot study. J Orthop Surg Res, 2010. 5: p. 93.
31. Wu, B.W., et al., Randomized control trial to evaluate the effects of acute testosterone administration in men on muscle mass, strength, and physical function following ACL reconstructive surgery: rationale, design, methods. BMC Surg, 2014. 14: p. 102.
32. Metcalfe, D., et al., Anabolic steroids in patients undergoing total knee arthroplasty. BMJ Open, 2012. 2(5).
33. Frisoli, A., Jr., et al., The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis: a double-blind, randomized, placebo-controlled clinical trial. J Gerontol A Biol Sci Med Sci, 2005. 60(5): p. 648-53.
34. Need, A.G., T.C. Durbridge, and B.E. Nordin, Anabolic steroids in postmenopausal osteoporosis. Wien Med Wochenschr, 1993. 143(14-15): p. 392-5.
35. Geusens, P., Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Clin Rheumatol, 1995. 14 Suppl 3: p. 32-9.
36. Geusens, P. and J. Dequeker, Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone Miner, 1986. 1(4): p. 347-57.
37. Hamdy, R.C., et al., Nandrolone decanoate for men with osteoporosis. Am J Ther, 1998. 5(2): p. 89-95.
38. Vanderschueren, D., et al., Sex steroid actions in male bone. Endocr Rev, 2014: p. er20141024.
39. Snyder, P.J., et al., Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab, 1999. 84(6): p. 1966-72.
40. Meriggiola, M.C., et al., Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. J Sex Med, 2008. 5(10): p. 2442-53.
41. Kenny, A.M., et al., Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc, 2010. 58(6): p. 1134-43.
42. Clarke, B.L. and S. Khosla, Androgens and bone. Steroids, 2009. 74(3): p. 296-305.
43. Basurto, L., et al., Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. Aging Male, 2008. 11(3): p. 140-5.
44. Anderson, F.H., R.M. Francis, and K. Faulkner, Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone, 1996. 18(2): p. 171-7.
45. Amory, J.K., et al., Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab, 2004. 89(2): p. 503-10.
46. Demling, R. and L. De Santi, Closure of the "non-healing wound" corresponds with correction of weight loss using the anabolic agent oxandrolone. Ostomy Wound Manage, 1998. 44(10): p. 58-62, 64, 66 passim.
47. Demling, R.H. and D.P. Orgill, The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J Crit Care, 2000. 15(1): p. 12-7.
48. Sotto, J.J., et al., [Androgens and prolonged complete remissions in acute non lymphoblastic leukemias. Results of a systematic treatment with stanozolol associated with chemotherapy (author's transl)]. Nouv Rev Fr Hematol, 1975. 15(1): p. 57-72.
49. Hollard, D., et al., [Trial of androgen therapy in the treatment of non-lymphoblastic acute leukemia. First results]. Nouv Presse Med, 1976. 5(20): p. 1289-93.
50. Chen, C.T., et al., Muscle wasting in hemodialysis patients: new therapeutic strategies for resolving an old problem. ScientificWorldJournal, 2013. 2013: p. 643954.
51. Johansen, K.L., K. Mulligan, and M. Schambelan, Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA, 1999. 281(14): p. 1275-81.
52. Paul, A.K., et al., Androgen versus erythropoietin for the treatment of anaemia of pre-dialysis chronic kidney disease. Mymensingh Med J, 2012. 21(1): p. 125-8.
53. Pan, L., et al., Effects of anabolic steroids on chronic obstructive pulmonary disease: a meta-analysis of randomised controlled trials. PLoS One, 2014. 9(1): p. e84855.
54. Saha, B., G.C. Rajadhyaksha, and S.K. Ray, Beneficial effects of nandrolone decanoate in wasting associated with HIV. J Indian Med Assoc, 2009. 107(5): p. 295-9.
55. Morgentaler, A., et al., Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions. Mayo Clin Proc, 2016. 91(7): p. 881-96.
56. Perry, P.J., et al., Anabolic steroid use in weightlifters and bodybuilders: an internet survey of drug utilization. Clin J Sport Med, 2005. 15(5): p. 326-30.
57. McCabe, S.E., et al., Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys. Drug Alcohol Depend, 2007. 90(2-3): p. 243-51.
58. Kersey, R.D., Anabolic-androgenic steroid use among california community college student-athletes. J Athl Train, 1996. 31(3): p. 237-41.
59. Frati, P., et al., Anabolic Androgenic Steroid (AAS) related deaths: autoptic, histopathological and toxicological findings. Curr Neuropharmacol, 2015. 13(1): p. 146-59.
60. Nieminen, M.S., et al., Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J, 1996. 17(10): p. 1576-83.
61. Payne, J.R., P.J. Kotwinski, and H.E. Montgomery, Cardiac effects of anabolic steroids. Heart, 2004. 90(5): p. 473-5.
62. Haider, A., et al., Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol, 2015. 193(1): p. 80-6.
63. Morgentaler, A., et al., Testosterone Therapy and Cardiovascular Risk: Advances and Controversies. Mayo Clin Proc, 2014.
64. Turillazzi, E., et al., Side effects of AAS abuse: an overview. Mini Rev Med Chem, 2011. 11(5): p. 374-89.
65. Ip, E.J., et al., The Anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. Pharmacotherapy, 2011. 31(8): p. 757-66.
66. Baker, J.S., M.R. Graham, and B. Davies, Steroid and prescription medicine abuse in the health and fitness community: A regional study. Eur J Intern Med, 2006. 17(7): p. 479-84.
67. Sagoe, D., et al., Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis. Subst Abuse Treat Prev Policy, 2015. 10: p. 12.
68. Albertson, T.E., et al., The Changing Drug Culture: Use and Misuse of Appearance- and Performance-Enhancing Drugs. FP Essent, 2016. 441: p. 30-43.
69. Pomara, C., et al., Neurotoxicity by synthetic androgen steroids: oxidative stress, apoptosis, and neuropathology: A review. Curr Neuropharmacol, 2015. 13(1): p. 132-45.
70. Hakansson, A., et al., Anabolic androgenic steroids in the general population: user characteristics and associations with substance use. Eur Addict Res, 2012. 18(2): p. 83-90.
71. Ip, E.J., et al., Characteristics and Behaviors of Older Male Anabolic Steroid Users. J Pharm Pract, 2015. 28(5): p. 450-6.